Annelien Van Dalem

Annelien Van Dalem serves as a Clinical Professor in the Department of Clinical Biology within the Faculty of Medicine and Pharmacy at Vrije Universiteit Brussel. Her clinical practice is based at University Hospital Brussels (UZB) where she maintains dual expertise in Pharmaceutical and Pharmacological Sciences alongside Clinical Biology. With an ORCID identifier (0000-0003-2304-5298) and active research profile through 2025, she represents a key figure in diabetes research and clinical laboratory medicine at this Belgian academic institution.

Dr. Van Dalem's research program centers on Type 1 Diabetes Mellitus with 100% research footprint concentration according to institutional metrics. Her work specifically investigates autoantibodies (64% research footprint), C-Peptide dynamics (64%), and therapeutic responses to agents like otelixizumab (49%). Additional expertise includes Zinc Transporter 8 (30%), Ion-Selective Electrode technology (24%), and Glucose monitoring systems (22%). Her laboratory focuses on early biological markers for diabetes prediction, complications assessment, and contribution to prevention trial design through epidemiological approaches.

Analysis of her publication record reveals a clear research trajectory spanning clinical chemistry methodology and diabetes pathophysiology. Recent work demonstrates increasing focus on continuous glucose monitoring technologies and therapeutic response prediction, while maintaining strong contributions to analytical interference issues in laboratory medicine. Her collaborative network includes major diabetes research groups across Belgium with significant work on otelixizumab trials and beta cell function preservation.

Scientific recognition includes:

• Award 'Bank J. Van Breda & C°' (2011)

Dr. Van Dalem actively supervises graduate research, most recently co-advising Janssens, A.'s 2024 Master's thesis on maglumi X3 platform validation for multiple analytes. Her institutional activities show extensive participation in professional development through 66 recorded events (2017-2025), including 32 conference participations and 29 workshop engagements. Current activities focus on AI applications in clinical biology, viral hepatitis diagnostics, HLA typing, and multiple myeloma diagnostics.

Her laboratory maintains dual research streams: one focused on diabetes biomarker discovery and validation, and another addressing analytical challenges in clinical chemistry including biotin interference and ion-selective electrode measurement accuracy. Recent collaborative work extends into cardiovascular outcomes research as evidenced by the 2025 FFRCT registry analysis.